The Phacilitate Young Scientist Award is presented annually for significant research contributions to the field of C&G therapy.
This award is for those with 3-7 years of experience since completion of university course and who are less than 37 years old on January 1st 2023
This award is nomination based, and you can nominate yourself or someone you work with.
The ‘Manufacturing Tech Disruptor of the Year’ award is presented to a company or an academic lab who have helped improve and simplify the manufacturing process through innovative new technology. We want to hear from trail blazers who are leading the way for the next generation of therapies.
The Patient Advocacy Award is awarded to organisations who foster awareness for C&G therapies and support those going through treatment. This award is targeted to companies who place the patient at the heart of their development and patient advocacy organisations who are dedicated to spreading awareness of the potential of CGT.
The DE&I Initiative of the Year is awarded to an organisation initiating and leading action to remove barriers and improve the working experience and engagement levels of their employees.
This award recognises sustainable development in the cell and gene therapy industry through innovative and sustainable use of resources and prioritises the needs of the wider environment and society. This can be a reduced carbon footprint, or energy saving products and methods. This can also include the adoption of a scheme that has made a difference to the attitudes and behaviour of staff and resulted in a benefit to the environment, or a new partnership that demonstrates tangible evidence of environmental benefit. This can be on a single project, across a series of projects, or through a change process within an organisation.
This award recognises biotech championing therapeutic innovation in cell and gene therapy. The therapeutic must, at a minimum, have phase 1 data and show its potential impact to patients in the future.
The Phacilitate Lifetime Achievement Award has been voted for by the Phacilitate community and our judges, and will be awarded to Carl June for his groundbreaking work inventing and developing adoptive cell therapy, demonstrating CAR T cells induce remission, and even cures, in advanced cancer.